Interestingly, EGF seems to be a prognostic factor in CRC independently of both activating RAS/RAF mutations and cetuximab treatment47, suggesting a role of EGF outside of the MAPK/RAS/RAF axis, possibly adding a second explanatory approach. The gene discussed is EGF; the disease is colorectal carcinoma.